Wall Street experts predict that Intuitive Surgical (ISRG) may climb by 29.72%: Consider this information before making an investment decision

Intuitive Surgical (ISRG): Analyst Price Targets Suggest Room for Growth

Intuitive Surgical, Inc. (ISRG) ended its most recent trading session at $479.27, reflecting a modest 0.1% gain over the last month. Despite this slight uptick, analysts on Wall Street believe the stock could climb much higher, with an average price target of $621.70—implying a potential increase of nearly 30%.

Analyst Price Target Range and Agreement

The consensus price target is based on 27 short-term forecasts, which span from $440.00 at the low end to $750.00 at the high end. The standard deviation of these estimates is $62.11, highlighting the degree of variation among analysts. While the lowest projection suggests an 8.2% decrease from current levels, the most optimistic outlook points to a possible 56.5% gain. Notably, a smaller standard deviation signals stronger agreement among analysts regarding the stock’s future direction.

Limitations of Consensus Price Targets

Although many investors look to consensus price targets for guidance, relying solely on these figures can be risky. The accuracy and impartiality of analyst price targets have often been called into question, making it important to consider other factors before making investment decisions.

Positive Earnings Revisions Strengthen Bullish Case

Beyond the encouraging price targets, analysts have recently shown increased confidence in ISRG’s earnings outlook. Upward revisions to earnings estimates are generally seen as a positive indicator for future stock performance, even if they don’t specify the exact magnitude of potential gains.

Price, Consensus, and EPS Surprise

Understanding Analyst Price Targets

Academic research from various institutions suggests that price targets can often mislead investors rather than provide accurate guidance. Studies have found that, regardless of how closely analysts’ estimates align, these targets rarely predict a stock’s actual trajectory.

Despite their expertise in evaluating company fundamentals and industry trends, analysts sometimes set overly optimistic price targets. This is often influenced by their firms’ business interests, which can lead to inflated projections.

However, when price targets are closely grouped—reflected by a low standard deviation—it indicates a strong consensus among analysts about the stock’s likely movement. While this doesn’t guarantee the stock will reach the average target, it can serve as a useful starting point for further research into the company’s fundamentals.

In summary, while price targets can offer some insight, investors should approach them with caution and avoid basing investment decisions solely on these figures.

Why ISRG May Have More Upside Ahead

Analysts have become increasingly optimistic about Intuitive Surgical’s earnings potential, as shown by a recent wave of upward revisions to EPS estimates. Historically, positive changes in earnings forecasts have been closely linked to short-term stock price gains.

In the past month, the Zacks Consensus Estimate for ISRG’s current-year earnings has risen by 0.4%, with one upward revision and no downward adjustments.

ISRG currently holds a Zacks Rank #1 (Strong Buy), placing it among the top 5% of over 4,000 stocks ranked by Zacks based on earnings estimate trends. This ranking, backed by an audited track record, provides a more reliable signal of near-term upside potential.

While the consensus price target alone may not precisely predict ISRG’s future gains, the direction suggested by recent analyst activity offers a promising outlook.

Discover Zacks’ Top 10 Stocks for 2026

There’s still time to get early access to Zacks’ top 10 stock picks for 2026. Curated by Director of Research Sheraz Mian, this portfolio has delivered remarkable and consistent returns.

Since its inception in 2012 through November 2025, the Zacks Top 10 Stocks have soared by 2,530.8%, far outpacing the S&P 500’s 570.3% gain.

Sheraz has reviewed 4,400 companies covered by Zacks and selected the best 10 to buy and hold for 2026. Don’t miss your chance to see these newly released high-potential stocks.

Get More Stock Recommendations

Looking for more investment ideas? Download Zacks’ report on the 7 Best Stocks for the Next 30 Days.